secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2026-08-14T20:35:17+00:00
Accession:  0001213900-26-090183
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity Q2 2026: cash $26.9M, loss $3.7M; stenoparib manufacturing completed
-----------------------------------------------------------------------------

- Cash and restricted cash $26.9M at June 30, 2026, up from $14.7M a year ago.
- Q2 comprehensive loss $3.7M vs $4.2M; six-month loss $6.5M vs $7.2M.
- R&D expenses $1.3M (down from $2.3M); G&A $1.3M (down from $1.8M).
- Completed Phase 3-ready stenoparib API manufacturing campaign in July 2026, ahead of schedule.
- USPTO granted key patent for stenoparib DRP companion diagnostic, exclusivity to 2042.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000121390026090183/0001213900-26-090183-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000121390026090183/ea0302157-8k_allarity.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-090183

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer